Product Acquisition

Alliance Pharma PLC
15 September 2006

For immediate release                                          15 September 2006


                               ALLIANCE PHARMA PLC

                      ('Alliance Pharma' or 'the Company')

                   Further expansion of dermatology portfolio


Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has acquired marketing rights in the UK and Ireland for the
woundcare treatment Permitabs(R), adding a further product to the Company's
rapidly growing dermatology portfolio.

Permitabs(R), which is used for the cleansing and deodorising of eczematous
lesions and wounds, has annualised sales of £275,000. The product, whose sales
have been growing at more than 20 per cent a year, was acquired from Derma UK
Ltd for a one-off cash consideration of £800,000, financed through the Company's
senior debt facility provided by the Bank of Scotland.

Permitabs(R), which is included in the British National Formulary of recommended
products, is a tablet containing potassium permanganate and is made into a
solution by nursing staff for the treatment of patients. The product will be
marketed by Alliance's specialist dermatology sales force, which has an
increasing number of prescription products to sell and cross sell to
dermatologists.


John Dawson, Alliance Pharma's Chief Executive, commented: 'This latest
acquisition gives further depth to our dermatology franchise, which in a
relatively short period of time has become a significant growth area for the
Company. We continue to seek and evaluate dermatology products to increase
further the range of products marketed by our specialist dermatology sales
force.'


For further information:

Alliance Pharma plc                                         + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich


Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.



                      This information is provided by RNS
            The company news service from the London Stock Exchange